Protection Duration of COVID-19 Vaccines: Waning Effectiveness and Future Perspective

Overview

Journal Front Microbiol

Specialty Microbiology

Date 2022 Mar 11

PMID 35273584

Authors

Chunlan Zhuang

Xiaohui Liu

Qi Chen

Yuxin Sun

Yingying Su

Shoujie Huang

Ting Wu

Ningshao Xia

Affiliations

Soon will be listed here.

Abstract

The coronavirus disease 2019 (COVID-19) vaccines have very successfully decreased the disease risk as we know; some key information remains unknown due to the short development history and the lack of long-term follow-up studies in vaccinated populations. One of the unanswered issues is the protection duration conferred after COVID-19 vaccination, which appears to play a pivotal role in the future impact of pathogens and is critical to inform the public health response and policy decisions. Here, we review current information on the long-term effectiveness of different COVID-19 vaccines, persistence of immunogenicity, and gaps in knowledge. Meanwhile, we also discuss the influencing factors and future study prospects on this topic.

Citing Articles

Uptake and hesitancy of the second booster dose of COVID-19 vaccine among the general population in China after the surge period of the COVID-19 pandemic: a large-scale national study.

Liu X, Xin Y, Zhang L, Wu Y, Jing S, Dai Z BMC Public Health. 2025; 25(1):503.

PMID: 39920639 PMC: 11803999. DOI: 10.1186/s12889-025-21691-x.

New COVID-19 vaccination recommendations in Spain: Optimizing for next seasons.

Arrazola P, Fernandez Prada M, Gil A, Gomez Rial J, Hernan C, Menendez R Enferm Infecc Microbiol Clin. 2025; 43(1):36-46.

PMID: 39845334 PMC: 11752446. DOI: 10.1016/j.eimc.2024.08.012.

Effect of Homologous and Heterologous Booster in COVID-19 Vaccination.

Vukcevic M, Despot M, Nikolic-Kokic A, Blagojevic D, Nikolic M, Banko A Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770576 PMC: 11679259. DOI: 10.3390/ph17121734.

AI Promoted Virtual Screening, Structure-Based Hit Optimization, and Synthesis of Novel COVID-19 S-RBD Domain Inhibitors.

Gkekas I, Katsamakas S, Mylonas S, Fotopoulou T, Magoulas G, Tenchiu A J Chem Inf Model. 2024; 64(22):8562-8585.

PMID: 39535926 PMC: 11600510. DOI: 10.1021/acs.jcim.4c01110.

Dynamics of an SVEIR transmission model with protection awareness and two strains.

Chen K, Wei F, Zhang X, Jin H, Zhou R, Zuo Y Infect Dis Model. 2024; 10(1):207-228.

PMID: 39469221 PMC: 11513685. DOI: 10.1016/j.idm.2024.10.001.

References

Infantino M, Pieri M, Nuccetelli M, Grossi V, Lari B, Tomassetti F . The WHO International Standard for COVID-19 serological tests: towards harmonization of anti-spike assays. Int Immunopharmacol. 2021; 100:108095. PMC: 8403673. DOI: 10.1016/j.intimp.2021.108095. View

Krause P, Fleming T, Longini I, Peto R, Briand S, Heymann D . SARS-CoV-2 Variants and Vaccines. N Engl J Med. 2021; 385(2):179-186. PMC: 8262623. DOI: 10.1056/NEJMsr2105280. View

Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin J, Olsson A . Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020; 183(1):158-168.e14. PMC: 7427556. DOI: 10.1016/j.cell.2020.08.017. View

Barda N, Dagan N, Cohen C, Hernan M, Lipsitch M, Kohane I . Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021; 398(10316):2093-2100. PMC: 8555967. DOI: 10.1016/S0140-6736(21)02249-2. View

Tarke A, Sidney J, Methot N, Yu E, Zhang Y, Dan J . Impact of SARS-CoV-2 variants on the total CD4 and CD8 T cell reactivity in infected or vaccinated individuals. Cell Rep Med. 2021; 2(7):100355. PMC: 8249675. DOI: 10.1016/j.xcrm.2021.100355. View

Reynolds C, Pade C, Gibbons J, Butler D, Otter A, Menacho K . Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science. 2021; . PMC: 8168614. DOI: 10.1126/science.abh1282. View

Lustig Y, Zuckerman N, Nemet I, Atari N, Kliker L, Regev-Yochay G . Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel. Euro Surveill. 2021; 26(26). PMC: 8326656. DOI: 10.2807/1560-7917.ES.2021.26.26.2100557. View

Tan A, Linster M, Tan C, Bert N, Chia W, Kunasegaran K . Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep. 2021; 34(6):108728. PMC: 7826084. DOI: 10.1016/j.celrep.2021.108728. View

Li X, Wang W, Zhao X, Zai J, Zhao Q, Li Y . Transmission dynamics and evolutionary history of 2019-nCoV. J Med Virol. 2020; 92(5):501-511. PMC: 7166881. DOI: 10.1002/jmv.25701. View

10.

Thomas S, Moreira Jr E, Kitchin N, Absalon J, Gurtman A, Lockhart S . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med. 2021; 385(19):1761-1773. PMC: 8461570. DOI: 10.1056/NEJMoa2110345. View

11.

Chen J, Wang R, Wang M, Wei G . Mutations Strengthened SARS-CoV-2 Infectivity. J Mol Biol. 2020; 432(19):5212-5226. PMC: 7375973. DOI: 10.1016/j.jmb.2020.07.009. View

12.

Collier A, Yu J, McMahan K, Liu J, Chandrashekar A, Maron J . Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines. N Engl J Med. 2021; 385(21):2010-2012. PMC: 8531985. DOI: 10.1056/NEJMc2115596. View

13.

Kelada M, Anto A, Dave K, Saleh S . The Role of Sex in the Risk of Mortality From COVID-19 Amongst Adult Patients: A Systematic Review. Cureus. 2020; 12(8):e10114. PMC: 7523740. DOI: 10.7759/cureus.10114. View

14.

Khoury D, Wheatley A, Ramuta M, Reynaldi A, Cromer D, Subbarao K . Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models. Nat Rev Immunol. 2020; 20(12):727-738. PMC: 7605490. DOI: 10.1038/s41577-020-00471-1. View

15.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021; 397(10277):881-891. PMC: 7894131. DOI: 10.1016/S0140-6736(21)00432-3. View

16.

Nunes B, Rodrigues A, Kislaya I, Cruz C, Peralta-Santos A, Lima J . mRNA vaccine effectiveness against COVID-19-related hospitalisations and deaths in older adults: a cohort study based on data linkage of national health registries in Portugal, February to August 2021. Euro Surveill. 2021; 26(38). PMC: 8462036. DOI: 10.2807/1560-7917.ES.2021.26.38.2100833. View

17.

Chemaitelly H, Tang P, Hasan M, Almukdad S, Yassine H, Benslimane F . Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N Engl J Med. 2021; 385(24):e83. PMC: 8522799. DOI: 10.1056/NEJMoa2114114. View

18.

Falsey A, Frenck Jr R, Walsh E, Kitchin N, Absalon J, Gurtman A . SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. N Engl J Med. 2021; 385(17):1627-1629. PMC: 8461567. DOI: 10.1056/NEJMc2113468. View

19.

Dejnirattisai W, Zhou D, Supasa P, Liu C, Mentzer A, Ginn H . Antibody evasion by the P.1 strain of SARS-CoV-2. Cell. 2021; 184(11):2939-2954.e9. PMC: 8008340. DOI: 10.1016/j.cell.2021.03.055. View

20.

Tartof S, Slezak J, Fischer H, Hong V, Ackerson B, Ranasinghe O . Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021; 398(10309):1407-1416. PMC: 8489881. DOI: 10.1016/S0140-6736(21)02183-8. View